Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-014732
Filing Date
2025-04-21
Accepted
2025-04-21 16:15:36
Documents
20
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20044396x2_def14a.htm   iXBRL DEF 14A 1331422
3 logo_atai.jpg GRAPHIC 43339
4 logo_nauta.jpg GRAPHIC 14108
5 ny20044396x2_christiansig.jpg GRAPHIC 14070
6 ny20044396x2_pc01.jpg GRAPHIC 742837
7 ny20044396x2_pc02.jpg GRAPHIC 959595
8 ny20044396x2_ryansig.jpg GRAPHIC 27000
9 ny20044396x2_srinisig.jpg GRAPHIC 13823
  Complete submission text file 0001140361-25-014732.txt   6437399

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA atai-20250515.xsd EX-101.SCH 2125
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20044396x2_def14a_htm.xml XML 4696
Mailing Address WALLSTRASSE 16 BERLIN 2M 10179
Business Address WALLSTRASSE 16 BERLIN 2M 10179 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40493 | Film No.: 25853343
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)